Financial calendar 2007
financial statements on the following dates in 2007:
4th quarter results 2006: 13 February
Annual General Meeting: 6 March
1st quarter results 2007: 25 April
2nd quarter results 2007: 22 August
3rd quarter results 2007: 24 October
For further information, please contact:
CEO Øyvind S. Brekke, Navamedic
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40, Mobile: +47 91 19 81 64
CFO Bernt-Olav Røttingsens, Navamedic
E-mail: bor@navamedic.com
Office: +47 67 11 25 44 Mobile: +47 913 47 021
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. Navamedic`s product Glucomed®/Flexove(TM) has been approved across 25 EU/EEA states by European Medicines Agency (EMEA), as the first and only glucosamine based medicine against osteoarthritis. The company`s products will be sold through a network of sales, marketing and distribution partners. For more information, please see www.navamedic.com